Peptide Receptor Radionuclide Therapy with $^{67}$Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model

Carleen Cullinane1,2, Charmaine M. Jeffery3, Peter D. Roselt4, Ellen M. van Dam3, Susan Jackson2, Kevin Kuan5, Price Jackson4, David Binns4, Jessica van Zuylenk0m2, Matthew J. Harris3, Rodney J. Hicks1,2, and Paul S. Donnelly6

1Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; 2Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 3Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia; 4Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 5Molecular Imaging and Therapy Research Unit, SAHMRI, Adelaide, South Australia, Australia; and 6School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria, Australia

Peptide receptor radionuclide therapy (PRRT) using radiolabeled octreotate is an effective treatment for somatostatin receptor 2–expressing neuroendocrine tumors. The diagnostic and therapeutic potential of $^{64}$Cu and $^{67}$Cu, respectively, offers the possibility of using a single somatostatin receptor–targeted peptide conjugate as a theranostic agent. A sarcophagine cage amine ligand, MeCO-Sar (5-(8-methyl-3,6,10,13,16,19-hexaazacyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid), conjugated to (Tyr$^3$)octreotate, called $^{64}$Cu-CuSarTATE, was demonstrated to be an imaging agent and potential prospective dosimetry tool in 10 patients with neuroendocrine tumors. This study aimed to explore the antitumor efficacy of $^{67}$Cu-CuSarTATE in a preclinical model of neuroendocrine tumors and compare it with the standard PRRT agent, $^{177}$Lu-LuTATE, either as a single fraction or divided into 2 fractions over 2 wk. The antitumor activity of $^{67}$Cu-CuSarTATE was well tolerated in BALB/c nude mice and highly efficacious against AR42J tumors in vivo. Administration of $^{67}$Cu-CuSarTATE and $^{177}$Lu-LuTATE divided into 2 fractions over 2 wk was more efficacious than administration of a single fraction. The antitumor activity of $^{67}$Cu-CuSarTATE in the AR42J tumor model demonstrated the suitability of this novel agent for clinical assessment in the treatment of somatostatin receptor 2–expressing neuroendocrine tumors.

Key Words: radiopharmaceuticals; $^{64}$Cu; $^{67}$Cu; peptide receptor radionuclide therapy; theranostics

DOI: 10.2967/jnumed.120.243543

Overexpression of the somatostatin subtype 2a receptor on certain types of neuroendocrine tumors, as well as neuroblastoma, pheochromocytoma/paraganglioma, Merkel cell carcinoma, and meningioma, leads to this receptor being a valid target for diagnostic imaging and peptide receptor radionuclide therapy (PRRT). Diagnostic PET imaging with the $^{68}$Ga(III) ($t_{1/2} = 68$ min) complex of DOTATATE, in which the macrocycle DOTA is conjugated to Tyr$^3$-octreotate, an 8-amino-acid peptide analog of somatostatin, has emerged as a valuable tool to identify patients suitable for PRRT with the $\beta^-$-emitting lutetium complex $^{177}$Lu-LuDOTA-Tyr$^3$-octreotate ($^{177}$Lu-LuTATE) ($t_{1/2} = 2.7$ d). The safety and efficacy of PRRT relies on selectively delivering the highest possible dose of radiation to the tumor while sparing organs from radiation toxicity, particularly the kidney, which is a critical target organ for radionuclide therapy. Accurate prospective dosimetry would allow prescription of an administered activity that maximizes therapeutic efficacy within the tolerance of organs such as the kidney. The use of a short-lived radionuclide ($^{64}$Ga, $t_{1/2} = 68$ min) to predict dosimetry for subsequent therapy with the long-lived radionuclide $^{177}$Lu (half-life $t_{1/2} = 6.65$ d, $\beta^- = 100\%$, $E_{\beta^-}$ (mean) = 134 keV) introduces limitations in modeling dosimetry. Furthermore, the use of 2 different chemical elements (gallium and lutetium) with different chemistries can lead to inconsistent tissue biodistribution, as it is likely that peptide–metal complex assemblies prepared with different metal ions do not have the same binding and internalization interactions and altered excretory pathways ($6–8$). Furthermore, the use of the same element for both imaging and therapy would represent an important advance for radionuclide therapy, particularly if the $t_{1/2}$ of the diagnostic agent is sufficient to evaluate clearance kinetics from critical target organs. There are 2 copper radionuclides, $^{64}$Cu and $^{67}$Cu, that offer a matched theranostic pair.
Positron-emitting $^{64}$Cu ($t_{1/2} = 12.7$ h, $\beta^+ = 17.4\%$, $E_{\beta^+} = 278$ keV) can be used as a companion diagnostic agent to plan use of PRRT using the $\beta^-$-emitting $^{67}$Cu ($t_{1/2} = 61.9$ h, $\beta^+ = 100\%$, $E_{\beta^+} = 141$ keV) (9–11). The $\beta^-$-emissions of $^{67}$Cu have a mean range of 0.2 mm and are appropriate for the treatment of small tumors down to 5 mm in diameter and disseminated metastatic disease (12–14). $^{64}$Cu has a higher fraction of $\gamma$-emission than $^{177}$Lu, but the mean energies of their relevant peaks are similar ($^{64}$Cu: 185 keV, 49%, and 93 keV, 16%; $^{177}$Lu: 208 keV, 11%, and 113 keV, 6%) (15), making it suitable for posttreatment whole-body scintigraphy for calculation of percentage retention of administered dose on planar or quantitative SPECT dosimetry.

Pioneering studies that identified the therapeutic potential of $^{64}$Cu used derivatives of the tetraazaamacrocycles, such as cyclam, to coordinate the copper(II) radionuclide (16). In one example, a monofunctionalized cyclam derivative, 4-(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]benzoic acid, was conjugated to an antibody against anticarcinembryonic antigen (AB35) and the conjugate radiolabeled with $^{64}$Cu. Evaluation of this conjugate in a mouse LoVo tumor model demonstrated high tumor uptake (15% $\pm$ 3% injected activity [%IA/g] after 24 h and 32 $\pm$ 7 [%IA/g] after 96 h) (17). This work was extended to a comparison of the biodistribution of $^{64}$Cu-labeled AB35 with $^{125}$I-labeled AB35 in 6 patients with primary colorectal cancer. The $^{64}$Cu conjugate had higher tumor uptake than the radiiodinated antibody but also high nonspecific liver and bowel uptake (18).

The therapeutic efficacy of both $^{64}$Cu- and $^{66}$Cu-labeled mouse antihuman colorectal cancer monoclonal antibody (called I235) was investigated in a GW39 human colon carcinoma carried in hamsters. Both the $^{64}$Cu- and the $^{66}$Cu-labeled antibodies were able to cause complete remission in small tumors, but to account for the different physical decay and radioactive half-lives of $^{64}$Cu and $^{66}$Cu, 5 times more $^{66}$Cu agent was administrated (9). In another demonstration of the therapeutic potential of $^{64}$Cu, a monoclonal antibody (Lym-1) that preferentially targets malignant tissue was functionalized with a derivative of the tetraazaamacrocycle 1,4,7,11-tetraaza-cyclotetradecane-$N,N',N''$,$N'''$-tetraacetic acid, was conjugated to an antibody against Lym-1 that preferentially targets malignant tissue was functionalized with a derivative of the tetraazamacrocycle 1,4,7,11-tetraazacyclotetradecane-$N,N',N''$,$N'''$-tetraacetic acid (TETA) to permit radiolabeling with $^{64}$Cu. An evaluation of this conjugate in 11 lymphoma patients resulted in tumor regressions despite the fact that patients received only imaging doses (126–477 MBq) (19,20). The potential for PRRT with a $^{64}$Cu-labeled somatostatin-targeting complex, $^{64}$Cu-CuTETA-TATE, has been demonstrated previously (21). Briefly, SarTATE was prepared by Auspep (Tullamarine) using a modified version of a method reported previously (22). $^{64}$Cu-CuCl$_2$ (700 MBq in 0.05 M HCl) was provided by the Molecular Imaging and Therapy Research Unit of the South Australian Health and Medical Research Institute. $^{64}$Cu-CuCl$_2$ was provided by Idaho Accelerator Center of Idaho State University as a solution (54 GBq) in 0.05–0.1 M HCl. Lu-LuTATE was prepared by the in-house radiopharmacy of Peter MacCallum Cancer Centre following standard protocols (22).

Preparation of $^{64}$Cu-CuSarTATE

$^{64}$Cu-CuSarTATE was prepared by using a modified version of a previously described method (23,30). Briefly, $^{64}$Cu-CuCl$_2$ (700 MBq in 0.05 M HCl [300 $\mu$L]) was added to SarTATE (20 $\mu$g, 13.7 nmol) in a solution of 10% ethanol in 0.1 M ammonium acetate (5 mL) containing gentisic acid, sodium salt (38 mg). The reaction mixture was incubated for 25 min at room temperature and then passed through a Strata X 33-$\mu$m polymeric reverse-phase cartridge (Phenomenex, Inc.). Cartridge-retained $^{64}$Cu-CuSarTATE was rinsed with saline for injection and then eluted with ethanol followed by saline for injection into a vial. The contents of this vial were filtered through a 0.22-$\mu$m filter. $^{64}$Cu-CuSarTATE was recovered in 60%–80% radiochemical yield with more than 95% radiochemical purity.

Preparation of $^{67}$Cu-CuSarTate

Briefly, $^{67}$Cu-CuCl$_2$ (~4 GBq, 0.05–0.1 M HCl) was added to SarTATE (60 $\mu$g, 41.2 nmol) in a solution of 10% ethanol in 0.1 M ammonium acetate (5 mL) containing gentisic acid, sodium salt (38 mg). The reaction mixture was incubated for 30 min at room temperature and then passed through a Strata-X 33-$\mu$m polymeric reverse-phase cartridge (30 mg). Cartridge-retained $^{67}$Cu-CuSarTATE was rinsed with saline for injection before elution with ethanol into a vial containing saline for injection. The contents of this vial were passed through a 0.22-mm filter to give $^{67}$Cu-CuSarTATE in 60%–80% radiochemical yield with more than 95% radiochemical purity.

PET Imaging and Biodistribution Studies

All in vivo studies were performed with the approval of the Peter MacCallum Cancer Centre Animal Experimentation Ethics Committee.
and in accordance with the Australian code for the care and use of animals for scientific purposes, eighth edition (2013). AR42J cells were obtained from the American Type Culture Collection. Cells (3 × 10^6) in 50% Matrigel (Corning) in phosphate-buffered saline were implanted subcutaneously into the right flank of 6- to 7-wk-old female BALB/c nude mice (Australian Bioresources). Once tumors reached a volume of 100–150 mm³, the mice were injected intravenously with 3 MBq (0.24 nmol) of ⁶⁴Cu-CuSarTATE. At 1 and 4 h after injection, the mice were anesthetized with 2% isoflurane in oxygen and placed into a G8 PET/CT scanner (Perkin Elmer). A CT image was then acquired over 1 min, followed by a 10-min static PET image. The PET images were reconstructed using the on-board maximum-likelihood expectation maximization algorithm and then analyzed using the VivoQuant (Invicro) software package. On completion of the 4 h of imaging, the mice were euthanized. Organs (blood, lungs, heart, liver, kidneys, muscle, spleen, and tumor) were excised and weighed, and the amount of radioactivity present in each organ was quantified using a Capintec (Captus 4000e) γ-counter. Data are presented as %IA/g tissue.

In Vivo Therapy Studies

In the therapy experiments, BALB/c nude female mice with subcutaneous AR42J xenografts (100–150 mm³) were intravenously injected with vehicle (saline), 5 MBq (0.07 nmol) of ¹⁷⁷Lu-LuTATE, or 30 MBq (0.37 nmol) of ⁶⁴Cu-CuSarTATE in a final volume of 100 μL (n = 7 for each group), or they were intravenously injected with vehicle (saline), 30 MBq (0.4 nmol) of ¹⁷⁷Lu-LuTATE, or 30 MBq (2.2 nmol) of ⁶⁴Cu-CuSarTATE either as a single administration or as a fractionated dose 14 d apart (15 MBq × 2) (n = 8 for each group). The mice were monitored twice weekly for tumor growth using calipers and evaluation of general health. They were euthanized when tumor volume exceeded 1,200 mm³. Tumor volume was calculated as length (mm) × width (mm) × height (π/6).

Data Analysis

Percentage tumor growth inhibition was calculated as 100 × (1 − ΔT/ΔC), where ΔC and ΔT were determined by subtracting the mean tumor volume (in the vehicle control and treated groups, respectively) on day 1 of treatment from the mean tumor volume on the last day all mice remained in the study. Statistical analysis was performed using GraphPad Prism, version 8.0. An ANOVA was performed, followed by a Dunnett post hoc test to compare tumor growth in the treated groups with that in the vehicle control group. Survival curves were analyzed using the Mantel–Cox log-rank test, where survival was defined as time for a tumor to reach a volume of at least 1,200 mm³.

RESULTS

Both ⁶⁴Cu-CuSarTATE and ⁶⁴Cu-CuSarTATE could be prepared in ammonium acetate buffer at room temperature in 30 min to give the complexes in 60%–80% radiochemical yield with more than 95% radiochemical purity.

⁶⁴Cu-CuSarTATE Has High Tumor Uptake in Somatostatin Receptor 2-Positive AR42J Xenograft Model

PET images were acquired after administration of ⁶⁴Cu-CuSarTATE (3 MBq, 0.24 nmol) via tail-vein injection to AR42J tumor–bearing female BALB/c nude mice. PET/CT images at 1 and 4 h after injection revealed very high tumor uptake and low background (Fig. 2). The tumors were clearly identified at 1 h after injection (SUV_{max} = 16.3 ± 1.7 at 1 h after injection), with excellent tumor to background ratios (66 ± 7 at 1 h after injection). Clearance over 4 h led to a further increase in the tumor-to-background ratios (76 ± 7; P = 0.027 vs. 1 h). The high tumor uptake was confirmed with an ex vivo biodistribution analysis in which the animals were euthanized after imaging at 4 h after injection and the amount of radioactivity in the tumor and organs was quantified (Fig. 2B). The tumor uptake 4 h after injection was 61.8 ± 2.4 %IA/g. Kidney uptake was 16.0 ± 0.7 %IA/g, and lung uptake was 12.2 ± 0.8 %IA/g.

⁶⁴⁷Cu-CuSarTATE Is Highly Efficacious Against AR42J Tumors In Vivo

Mice were inoculated with AR42J cells, and once the tumors reached a volume of approximately 150 mm³, the mice were randomized to receive saline, ¹⁷⁷Lu-LuTATE, or ⁶⁷Cu-CuSarTATE via intravenous injection. The treatments were well tolerated, causing only a transient reduction in animal body weight that did not exceed 5% of that at baseline (Fig. 3A). Seven days after a single administration of ⁶⁷Cu-CuSarTATE (5 MBq, 0.37 nmol), tumor growth was inhibited by 75% (P = 0.0001 vs. control) compared with vehicle control (Fig. 3B). Administration of ¹⁷⁷Lu-LuTATE (5 MBq) inhibited tumor growth by 89% (P ≤
Survival, defined as the time to a tumor volume of more than 1,200 mm$^3$, was extended from 12 d in the control group to 21 d after treatment with both $^{67}$Cu-CuSarTATE and $^{177}$Lu-LuTATE (Fig. 3C). In a second study, the efficacy of fractionated delivery of PRRT was assessed. AR42J tumor-bearing mice were treated with a total of 30 MBq of $^{67}$Cu-CuSarTATE or $^{177}$Lu-LuTATE, either as a single intravenous injection or as two 15-MBq fractions 2 wk apart. All treatments were well tolerated (Fig. 4A) and induced tumor stasis, with reinitiation of tumor growth seen earlier in the single-fraction–treated groups (Fig. 4B). Furthermore, treatment of tumors with 2 fractions significantly improved survival when compared with delivery as a single fraction ($^{67}$Cu-CuSarTATE: 47 vs. 36 d [$P = 0.036$]; $^{177}$Lu-LuTATE: 46 vs. 29 d [$P = 0.00$]; Fig. 4C). Equivalent efficacy was observed between $^{67}$Cu-CuSarTATE and $^{177}$Lu-LuTATE after treatment on both the single and the fractionated schedules ($P = $ not statistically significant).

**DISCUSSION**

A sarcophagine cage amine ligand, MeCOSar (5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]hexadec-1-ylaminomethyl)-5-oxopenfanoic acid) conjugated to (Tyr$^3$)-octreotate ($^{64}$Cu-CuSarTATE) was demonstrated to be an effective imaging agent and potential prospective dosimetry tool in 10 patients with neuroendocrine tumors ($^{30}$). In this study, we aimed to investigate the therapeutic potential of $^{67}$Cu-CuSarTATE. The previous preclinical evaluation of $^{64}$Cu-CuSarTATE for PET imaging of somatostatin-positive tumors ($^{29}$) used a tumor model in which somatostatin receptor 2 is overexpressed through viral transfection (A427-7) ($^{33}$). In this work, a different tumor cell line with endogenous expression of somatostatin receptor 2 (AR42J) was used. This cell line is commonly used as a model of neuroendocrine tumor because of high somatostatin receptor 2 expression and reliable growth as a xenograft. This cell line was derived from a spontaneous pancreatic tumor in rats. The effective tumor targeting of $^{64}$Cu-CuSarTATE in the AR42J model was confirmed by PET imaging before we proceeded with therapeutic evaluation of the ligand labeled with $^{67}$Cu. High tumor uptake was evident in the PET images at 1 h after injection, and retention of this uptake led to images at 4 h after injection with excellent tumor-to-background ratios (Fig. 2). The high tumor uptake was confirmed by an ex vivo biodistribution study ($62 \pm 2\%$IA/g, 4 h after injection).

Administration of either 5 or 30 MBq, either as a single or a fractionated dose, of $^{67}$Cu-CuSarTATE for Radionuclide Therapy • Cullinane et al. 1803
$^{67}$Cu-CuSarTATE demonstrated efficacy similar to that of the same activity of $^{177}$Lu-LuTATE. Both agents significantly reduced tumor volume and increased life span (Figs. 3 and 4). Fractionated-dose protocols can lead to reductions in tumor burden with decreased toxicity by delivering a high cumulative dose of activity to the tumor while allowing nontarget tissue to recover (21). It is also possible that cells in different phases of the cell cycle may be differentially sensitive to radiation and that, by fractionating doses, cells at different stages of the cell cycle may be more effectively targeted. Supporting the current clinical practice of performing several spaced cycles of PRRT; administration of a total of 30 MBq of $^{67}$Cu-CuSarTATE or $^{177}$Lu-LuTATE, as two 15-MBq fractions 2 wk apart, significantly improved survival over delivery as a single fraction of 30 MBq.

The increased fraction of $\gamma$-emission of $^{67}$Cu, when compared with $^{177}$Lu, leads to 3.2 times higher $\gamma$-exposure per decay with a slightly less penetrating mean energy and will result in a greater radiation cross dose to healthy tissues. This $\gamma$-cross exposure, however, has not been linked to adverse effects in $^{177}$Lu therapies, for which regions with primary uptake and exposure to $\beta$-electrons are most strongly implicated in tissue effects. The higher fraction of $\gamma$-emission for $^{67}$Cu may be beneficial in terms of SPECT imaging, potentially allowing dose verification after treatment by performance of SPECT with CT attenuation correction (34). By comparison, $^{180}$mIn has approximately 12-fold increased $\gamma$-emission per decay compared with $^{177}$Lu and, coupled with a greater mean $\gamma$-energy, raises several radiation protection considerations. In the United States, the Nuclear Regulatory Commission guidance indicates that up to 14 GBq of $^{67}$Cu can be administered on an outpatient basis if the external dose rate at 1 m is less than 0.22 mSv/h (35). Extrapolation of measured patient dose rate data has suggested no issue with release of patients who have received up to 5 GBq of $^{67}$Cu-CuSarTATE (36).

Importantly, $^{67}$Cu-CuSarTATE displayed efficacy similar to that of $^{177}$Lu-LuTATE. The energy of the $\beta^-$-emissions from $^{67}$Cu is similar to the $\beta^-$-emissions from $^{177}$Lu, but the significantly shorter $t_{1/2}$ of $^{67}$Cu (2.58 vs. 6.71 d) provides a higher dose-rate. The ability to perform prospective dosimetry is an advantage for agents that use the $^{64}$Cu/$^{68}$Cu theranostic pair, especially in patients with a large tumor burden (37) or impaired renal function and in the pediatric setting, where PRRT is an emerging treatment for advanced neuroblastoma (38). It is acknowledged that diagnostic imaging and therapy are often performed using different quantities of administered peptide, and this difference needs to be considered because biodistribution can change depending on the amount of peptide injected. However, initial data on the biodistribution and radiation dosimetry of $^{64}$Cu-CuSarTATE and $^{60}$Cu-CuSarTATE in meningioma patients showed similar tumor clearance for the 2 agents and consistent organ dose estimations (39,40). In terms of the potential translation of the $^{64}$Cu/$^{68}$Cu theranostic pair to clinical studies, it is pertinent that $^{64}$Cu is produced on a cyclotron and its $t_{1/2}$ enables distribution to sites without on-site radiochemistry facilities and permits imaging at later times points than is possible with $^{68}$Ga-based agents. In addition, because $^{60}$Cu can be produced with linear accelerators at high specific activity (>150 Ci/mg) and at radionuclide purity higher than 99%, its production is not reliant on nuclear reactors.

**CONCLUSION**

As anticipated, $^{67}$Cu-CuSarTATE is well tolerated in BALB/c nude mice and highly efficacious against AR42J tumors in vivo. Administration of $^{67}$Cu-CuSarTATE and $^{177}$Lu-LuTATE divided into 2 fractions over 2 wk was more efficacious than administration of a single fraction. The antitumor activity of $^{67}$Cu-CuSarTATE in the AR42J tumor model suggests that this novel agent warrants clinical assessment for the treatment of somatostatin-expressing neuroendocrine tumors.

**DISCLOSURE**

Charmaine Jeffery, Ellen van Dam, and Matthew Harris were or are employed by Clarity Pharmaceuticals, the licensee of the intellectual property for SarTATE. Charmaine Jeffery and Paul Donnelly have potential financial interests in Clarity Pharmaceuticals. Paul Donnelly is an inventor of intellectual property, in this area of research, which has been licensed from the University of Melbourne to Clarity Pharmaceuticals. Paul Donnelly serves on the Scientific Advisory Board of Clarity Pharmaceuticals. Unrelated to this project, Rodney Hicks has share options in Telix Radiopharmaceuticals that are held on behalf of the Peter MacCallum Cancer Centre. This study was partially funded by Clarity Pharmaceuticals. Paul Donnelly received funding from the Australian Research Council and the National Health and Medical Research Council (Australia), which funded aspects of this research. Rodney J. Hicks is the recipient of a National Health and Medical Research Council Practitioner Fellowship (APP1108050), which supported this work. The Australian Cancer Research Foundation provided a grant to fund the PET/CT scanner used in these studies. No other potential conflict of interest relevant to this article was reported.

**ACKNOWLEDGMENTS**

We thank Rachael Walker and Jeannette Schreuders (Peter MacCallum Cancer Centre) for expert technical assistance and Peter Eu (Peter MacCallum Cancer Centre) for synthesizing $^{177}$Lu-LuTATE. We also thank Jon Stoner (ISU Idaho Accelerator Center) for providing $^{67}$Cu.

**REFERENCES**


